Have a feature idea you'd love to see implemented?
Let us know!
PIRS Pieris Pharmaceuticals Inc
Price (delayed)
$16.855
Market cap
$22.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$18.71
Enterprise value
$2.52M
Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin
Highlights
Pieris Pharmaceuticals's quick ratio has soared by 107% YoY and by 9% from the previous quarter
The debt has shrunk by 100% YoY
The EPS has plunged by 52% from the previous quarter but it has grown by 37% YoY
The net income has declined by 47% since the previous quarter but it is up by 12% year-on-year
Pieris Pharmaceuticals's equity has shrunk by 54% YoY and by 15% QoQ
The revenue has contracted by 49% from the previous quarter and by 37% YoY
Key stats
What are the main financial stats of PIRS
Market
Valuations
Earnings
Shares outstanding
1.32M
Market cap
$22.25M
Enterprise value
$2.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.19
Price to sales (P/S)
1.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.12
Revenue
$20.87M
EBIT
-$23.82M
EBITDA
-$23.36M
Free cash flow
-$35.75M
Per share
Balance sheet
Liquidity
EPS
-$18.71
Free cash flow per share
-$27.52
Book value per share
$14.17
Revenue per share
$16.07
TBVPS
$19.28
Total assets
$25.05M
Total liabilities
$6.35M
Debt
$0
Equity
$18.71M
Working capital
$18.71M
Debt to equity
0
Current ratio
3.95
Quick ratio
3.36
Net debt/EBITDA
0.84
Margins
Efficiency
Dividend
EBITDA margin
-111.9%
Gross margin
100%
Net margin
-114.1%
Operating margin
-123.6%
Return on assets
-62.4%
Return on equity
-97.3%
Return on invested capital
-451%
Return on capital employed
-127.3%
Return on sales
-114.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PIRS stock price
How has the Pieris Pharmaceuticals stock price performed over time
Intraday
-0.85%
1 week
-0.56%
1 month
1.66%
1 year
-9.67%
YTD
15.76%
QTD
1.66%
Financial performance
How have Pieris Pharmaceuticals's revenue and profit performed over time
Revenue
$20.87M
Gross profit
$20.87M
Operating income
-$25.79M
Net income
-$23.82M
Gross margin
100%
Net margin
-114.1%
The net margin has shrunk by 187% QoQ and by 40% YoY
PIRS's operating margin has dropped by 159% since the previous quarter and by 11% year-on-year
The revenue has contracted by 49% from the previous quarter and by 37% YoY
The company's gross profit fell by 49% QoQ and by 37% YoY
Growth
What is Pieris Pharmaceuticals's growth rate over time
Valuation
What is Pieris Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.19
P/S
1.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.12
The EPS has plunged by 52% from the previous quarter but it has grown by 37% YoY
PIRS's P/B is 61% below its 5-year quarterly average of 3.1 but 53% above its last 4 quarters average of 0.8
Pieris Pharmaceuticals's equity has shrunk by 54% YoY and by 15% QoQ
The stock's P/S is 116% above its last 4 quarters average of 0.5 but 74% below its 5-year quarterly average of 4.2
The revenue has contracted by 49% from the previous quarter and by 37% YoY
Efficiency
How efficient is Pieris Pharmaceuticals business performance
PIRS's return on invested capital has dropped by 193% since the previous quarter
The ROS has plunged by 187% from the previous quarter and by 40% YoY
Pieris Pharmaceuticals's ROA has plunged by 110% YoY and by 107% from the previous quarter
PIRS's return on equity has dropped by 79% since the previous quarter and by 8% year-on-year
Dividends
What is PIRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PIRS.
Financial health
How did Pieris Pharmaceuticals financials performed over time
Pieris Pharmaceuticals's quick ratio has soared by 107% YoY and by 9% from the previous quarter
PIRS's current ratio has soared by 105% year-on-year
The debt is 100% lower than the equity
The debt has shrunk by 100% YoY
PIRS's debt to equity has plunged by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.